Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) Non Operating Income: 2019-2024

Historic Non Operating Income for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $23.8 million.

  • Keros Therapeutics' Non Operating Income rose 17.17% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.6 million, marking a year-over-year increase of 22.69%. This contributed to the annual value of $23.8 million for FY2024, which is 40.30% up from last year.
  • According to the latest figures from FY2024, Keros Therapeutics' Non Operating Income is $23.8 million, which was up 40.30% from $16.9 million recorded in FY2023.
  • Keros Therapeutics' 5-year Non Operating Income high stood at $23.8 million for FY2024, and its period low was -$383,000 during FY2021.
  • For the 3-year period, Keros Therapeutics' Non Operating Income averaged around $16.9 million, with its median value being $16.9 million (2023).
  • Per our database at Business Quant, Keros Therapeutics' Non Operating Income slumped by 134.07% in 2021 and then surged by 2,739.95% in 2022.
  • Over the past 5 years, Keros Therapeutics' Non Operating Income (Yearly) stood at $1.1 million in 2020, then tumbled by 134.07% to -$383,000 in 2021, then surged by 2,739.95% to $10.1 million in 2022, then spiked by 67.63% to $16.9 million in 2023, then soared by 40.30% to $23.8 million in 2024.